Most Read Articles
Jairia Dela Cruz, 3 days ago
Metabolic and bariatric surgery (MBS) leads to large and sustained reductions in, and even reversal of, multiple risk factors for future joint disease in adolescents with severe obesity and musculoskeletal pain, according to data from the Teen Longitudinal Assessment of Bariatric Surgery study.
Pearl Toh, 31 Dec 2019
Adding the neuraminidase inhibitor oseltamivir to usual care speeds up recovery from influenza-like illness by a day compared with usual care alone, with even greater benefits seen in older, sicker patients with comorbidities, according to the ALIC4E study.
23 Dec 2019
At a Menarini-sponsored symposium held during the Asian Pacific Society Congress, renowned cardiologist Prof John Camm provided the latest evidence for chronic stable angina with or without concomitant diseases, with a special focus on the antianginal agent ranolazine and combination therapies. The event was chaired and moderated by Dr Dante Morales from the University of the Philippines College of Medicine.
Pearl Toh, 6 days ago
Obeticholic acid significantly improves fibrosis and disease activity in patients with nonalcoholic steatohepatitis (NASH), a chronic liver disease currently with no approved therapy, according to an interim analysis of the landmark REGENERATE* study.

Inflammatory bowel disease factors in chronic kidney disease

04 Dec 2019

Inflammatory bowel disease (IBD) contributes to an increased risk of developing chronic kidney disease (CKD), with the risk highest for younger patients, as shown in a study. Meanwhile, the use of IBD medications does not offer a protective benefit.

Researchers used data from The Health Improvement Network and reviewed the medical records of 17,807 IBD patients and 63,466 matched controls in relation to the risk of developing CKD stages 3–5D. They also assessed the effect of using IBD medications such as 5-aminosalicylic acid (5-ASA), azathioprine and methotrexate on estimated glomerular filtration rate (eGFR).

In multivariable Cox proportional hazards models adjusted for risk factors associated with CKD, IBD showed an association with the risk of developing CKD in patients aged 16–77 years, with the risk notably decreasing with age.

Specifically, the adjusted hazard ratio for CKD declined from 7.88 (95 percent confidence interval [CI], 2.56–24.19) at age 16 years to 1.13 (95 percent CI, 1.01–1.25) at age 77 years.

On further analysis, exposure to neither 5-ASAs nor methotrexate produced a change in eGFR. On the other hand, azathioprine use led to a small increase in eGFR (0.32 mL/min/1.73 m2, 95 percent CI, 0.16–0.48).

In light of the findings, the researchers recommended including intermittent monitoring of renal function in all patients with IBD as part of usual care. More studies are needed to prospectively identify mediators of the CKD–IBD association.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Jairia Dela Cruz, 3 days ago
Metabolic and bariatric surgery (MBS) leads to large and sustained reductions in, and even reversal of, multiple risk factors for future joint disease in adolescents with severe obesity and musculoskeletal pain, according to data from the Teen Longitudinal Assessment of Bariatric Surgery study.
Pearl Toh, 31 Dec 2019
Adding the neuraminidase inhibitor oseltamivir to usual care speeds up recovery from influenza-like illness by a day compared with usual care alone, with even greater benefits seen in older, sicker patients with comorbidities, according to the ALIC4E study.
23 Dec 2019
At a Menarini-sponsored symposium held during the Asian Pacific Society Congress, renowned cardiologist Prof John Camm provided the latest evidence for chronic stable angina with or without concomitant diseases, with a special focus on the antianginal agent ranolazine and combination therapies. The event was chaired and moderated by Dr Dante Morales from the University of the Philippines College of Medicine.
Pearl Toh, 6 days ago
Obeticholic acid significantly improves fibrosis and disease activity in patients with nonalcoholic steatohepatitis (NASH), a chronic liver disease currently with no approved therapy, according to an interim analysis of the landmark REGENERATE* study.